Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Nizar J. Bahlis,Rachid Baz,Simon J. Harrison,Hang Quach,Shir-Jing Ho,Annette Juul Vangsted,Torben Plesner,Philippe Moreau,Simon Gibbs,Sheryl Coppola,Xiaoqing Yang,Abdullah Al Masud,Jeremy A. Ross,Orlando F. Bueno,Jonathan L. Kaufman

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

2021

Nizar J. Bahlis
Rachid Baz
Simon J. Harrison
Hang Quach
Shir-Jing Ho
Annette Juul Vangsted
Torben Plesner
Philippe Moreau
Simon Gibbs
Sheryl Coppola
Xiaoqing Yang
Abdullah Al Masud
Jeremy A. Ross
Orlando F. Bueno
Jonathan L. Kaufman

PURPOSEVenetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may ...

Keywords:

Dexamethasone
Refractory Multiple Myeloma
Oncology
in patient
Daratumumab
Internal medicine
Chromosomal translocation
Bortezomib
Venetoclax
Medicine
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations